ALRN stock forecast
Our latest prediction for Aileron Therapeutics, Inc.'s stock price was made on the April 1, 2019 when the stock price was at 1.83$.
In the short term (2weeks), ALRN's stock price should underperform the market by -1.58%. During that period the price should oscillate between -12.91% and +19.03%.
In the medium term (3months), ALRN's stock price should outperform the market by 6.87%. During that period the price should oscillate between -26.95% and +51.68%.Get email alerts
Create a solid portfolio with ALRN
About Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.66$ per share.
The book value per share is 2.23$
Three months stock forecastApril 1, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|